Clinical Trial Update: Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and pharmacokinetics of a recombinant Factor XIII in healthy volunteers has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder
• Congenital Factor Xiii Deficiency

Drugs mentioned

• Recombinant Factor XIII (Factor XIII, recombinant)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 1 | Status: COMPLETED